Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

TCTMD’s Top 10 Most Popular Stories for January 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

January 31, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL

Presentation ESC 2021

Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL

Presenter: Eduardo Ramacciotti

August 30, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

March 17, 2021

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.